Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
05 janv. 2024 16h05 HE
|
Senti Biosciences, Inc.
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024...